Document › Details

Roche. (2/3/10). "Press Release: ATLAS Biolabs GmbH Joins Roche NimbleGen’s Certified Service Provider Program for Targeted Enrichment". Madison, WI.

Region Region Berlin
  Country Germany
Organisations Organisation Atlas Biolabs GmbH
  Organisation 2 Roche NimbleGen Inc.
  Group Roche (Group)
Products Product NimbleGen Sequence Capture technology
  Product 2 Genome Sequencer FLX System™ (GS FLX)
Index terms Index term Certified Service Provider (programme)
  Index term 2 DNA sequencing
Person Person      
Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY ) has announced that ATLAS Biolabs GmbH, a Berlin, Germany-based company, has officially become a Certified Service Provider (CSP) for NimbleGen Sequence Capture. They will provide services for NimbleGen 454 Optimized Sequence Capture Arrays coupled with sequencing services on the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company. ATLAS Biolabs GmbH has passed a rigorous certification test plan to achieve precise experimental standards to officially join the Roche NimbleGen Certified Service Provider Program. Their certification marks the second genomic service provider to join the Roche NimbleGen CSP Program for Sequence Capture in Europe. They will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture workflow optimized for 454 GS FLX Titanium Series sequencing using 385K Arrays (capture of up to 5 Mb custom regions) and 2.1M Array (Human Exome and capture of up to 30 Mb custom regions).

"The decision to join the Roche NimbleGen CSP Program was a logical extension of our portfolio. Our customers are looking at targeted genomic sequencing and we wanted to provide them with a set of elite solutions for the necessary enrichment" said Prof. Dr. Peter Nurnberg, CEO of ATLAS Biolabs GmbH.

"Roche NimbleGen welcomes the latest addition, ATLAS Biolabs GmbH, to our CSP family for Sequence Capture. ATLAS Biolab's close ties with key opinion leaders across several key market segments in Germany, in addition to their established academic excellence, will further strengthen our position as a leader in the targeted resequencing market and drive future growth of the Roche NimbleGen business and service channel in Europe," said Jay Schiestle, Vice President of Manufacturing for Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com. For more information about 454 Life Sciences, please visit www.454.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About ATLAS Biolabs GmbH

ATLAS Biolabs GmbH, with offices and laboratories in Berlin and Cologne, is a leading European service provider of several high-throughput microarray-based applications such as targeted genomic enrichment, genome-wide expression analysis, SNP analysis, and CGH analysis, followed by high performance data processing and bioinformatics. The company's main mission is to deliver consistent, high-quality genomic services to their customers through the use of streamlined, formalized business processes. ATLAS Biolabs' commitment to quality includes the certification DIN EN ISO 9001:2008, which is a common global quality management standard.

For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, GS FLX TITANIUM, and NIMBLEGEN are trademarks of Roche.
Other brands or product names are trademarks of their respective holders.

   
Record changed: 2010-07-21

More documents for Atlas Biolabs GmbH

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top